Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $16.00 target price on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on ESPR. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, JMP Securities reissued a “market outperform” rating and set a $7.00 price objective on shares of Esperion Therapeutics in a report on Thursday, January 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $1.87 on Tuesday. The stock’s fifty day moving average is $2.24 and its two-hundred day moving average is $2.12. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The firm has a market capitalization of $368.46 million, a P/E ratio of -2.92 and a beta of 1.01.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Traphagen Investment Advisors LLC purchased a new position in Esperion Therapeutics during the 3rd quarter worth $27,000. Cibc World Markets Corp purchased a new position in Esperion Therapeutics in the fourth quarter valued at about $39,000. Versor Investments LP acquired a new stake in Esperion Therapeutics in the third quarter valued at $44,000. SJS Investment Consulting Inc. purchased a new position in shares of Esperion Therapeutics in the fourth quarter valued at $55,000. Finally, Boomfish Wealth Group LLC raised its stake in shares of Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 5,102 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.